Luna, a Serpentine Ventures portfolio company, has started pivotal trials for its automated insulin delivery system, designed for the 90% of people who don't use insulin pumps. This innovation aims to improve glucose control.
Luna, a Serpentine Ventures portfolio company, has started pivotal trials for its automated insulin delivery system, designed for the 90% of people who don't use insulin pumps. This innovation aims to improve glucose control.
